400 related articles for article (PubMed ID: 23995842)
1. Ubiquitin E3 ligase CRL4(CDT2/DCAF2) as a potential chemotherapeutic target for ovarian surface epithelial cancer.
Pan WW; Zhou JJ; Yu C; Xu Y; Guo LJ; Zhang HY; Zhou D; Song FZ; Fan HY
J Biol Chem; 2013 Oct; 288(41):29680-91. PubMed ID: 23995842
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
3. Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells.
Lan H; Tang Z; Jin H; Sun Y
Sci Rep; 2016 Apr; 6():24218. PubMed ID: 27063292
[TBL] [Abstract][Full Text] [Related]
4. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression.
Jia L; Li H; Sun Y
Neoplasia; 2011 Jun; 13(6):561-9. PubMed ID: 21677879
[TBL] [Abstract][Full Text] [Related]
5. Selective ubiquitylation of p21 and Cdt1 by UBCH8 and UBE2G ubiquitin-conjugating enzymes via the CRL4Cdt2 ubiquitin ligase complex.
Shibata E; Abbas T; Huang X; Wohlschlegel JA; Dutta A
Mol Cell Biol; 2011 Aug; 31(15):3136-45. PubMed ID: 21628527
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
Yao WT; Wu JF; Yu GY; Wang R; Wang K; Li LH; Chen P; Jiang YN; Cheng H; Lee HW; Yu J; Qi H; Yu XJ; Wang P; Chu YW; Yang M; Hua ZC; Ying HQ; Hoffman RM; Jeong LS; Jia LJ
Cell Death Dis; 2014 Feb; 5(2):e1059. PubMed ID: 24525735
[TBL] [Abstract][Full Text] [Related]
7. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
8. The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.
Vanderdys V; Allak A; Guessous F; Benamar M; Read PW; Jameson MJ; Abbas T
Mol Cancer Ther; 2018 Feb; 17(2):368-380. PubMed ID: 28838998
[TBL] [Abstract][Full Text] [Related]
9. MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma.
Zhang Y; Shi CC; Zhang HP; Li GQ; Li SS
Oncotarget; 2016 Jul; 7(29):45263-45274. PubMed ID: 27223074
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Luo Z; Pan Y; Jeong LS; Liu J; Jia L
Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
[TBL] [Abstract][Full Text] [Related]
11. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
12. C/EBPα regulates CRL4(Cdt2)-mediated degradation of p21 in response to UVB-induced DNA damage to control the G1/S checkpoint.
Hall JR; Bereman MS; Nepomuceno AI; Thompson EA; Muddiman DC; Smart RC
Cell Cycle; 2014; 13(22):3602-10. PubMed ID: 25483090
[TBL] [Abstract][Full Text] [Related]
13. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells.
Lin JJ; Milhollen MA; Smith PG; Narayanan U; Dutta A
Cancer Res; 2010 Dec; 70(24):10310-20. PubMed ID: 21159650
[TBL] [Abstract][Full Text] [Related]
14. CDK1-dependent inhibition of the E3 ubiquitin ligase CRL4CDT2 ensures robust transition from S Phase to Mitosis.
Rizzardi LF; Coleman KE; Varma D; Matson JP; Oh S; Cook JG
J Biol Chem; 2015 Jan; 290(1):556-67. PubMed ID: 25411249
[TBL] [Abstract][Full Text] [Related]
15. The Identification of Potential Therapeutic Targets for Cutaneous Squamous Cell Carcinoma.
McHugh A; Fernandes K; Chinner N; Ibrahim AFM; Garg AK; Boag G; Hepburn LA; Proby CM; Leigh IM; Saville MK
J Invest Dermatol; 2020 Jun; 140(6):1154-1165.e5. PubMed ID: 31705877
[TBL] [Abstract][Full Text] [Related]
16. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells.
Mackintosh C; García-Domínguez DJ; Ordóñez JL; Ginel-Picardo A; Smith PG; Sacristán MP; de Álava E
Oncogene; 2013 Mar; 32(11):1441-51. PubMed ID: 22641220
[TBL] [Abstract][Full Text] [Related]
17. Suppression of glioblastoma by targeting the overactivated protein neddylation pathway.
Hua W; Li C; Yang Z; Li L; Jiang Y; Yu G; Zhu W; Liu Z; Duan S; Chu Y; Yang M; Zhang Y; Mao Y; Jia L
Neuro Oncol; 2015 Oct; 17(10):1333-43. PubMed ID: 25904638
[TBL] [Abstract][Full Text] [Related]
18. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth.
Luo Z; Yu G; Lee HW; Li L; Wang L; Yang D; Pan Y; Ding C; Qian J; Wu L; Chu Y; Yi J; Wang X; Sun Y; Jeong LS; Liu J; Jia L
Cancer Res; 2012 Jul; 72(13):3360-71. PubMed ID: 22562464
[TBL] [Abstract][Full Text] [Related]
19. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
Nawrocki ST; Kelly KR; Smith PG; Espitia CM; Possemato A; Beausoleil SA; Milhollen M; Blakemore S; Thomas M; Berger A; Carew JS
Clin Cancer Res; 2013 Jul; 19(13):3577-90. PubMed ID: 23633453
[TBL] [Abstract][Full Text] [Related]
20. Proliferating cell nuclear antigen interacts with the CRL4 ubiquitin ligase subunit CDT2 in DNA synthesis-induced degradation of CDT1.
Leng F; Saxena L; Hoang N; Zhang C; Lee L; Li W; Gong X; Lu F; Sun H; Zhang H
J Biol Chem; 2018 Dec; 293(49):18879-18889. PubMed ID: 30301766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
